

## **Astellas Announces Acquisition of Own Shares**

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, November 1, 2012 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

### Particulars

1. Reasons for the acquisition of own shares  
To improve capital efficiency and shareholder return.

2. Contents of acquisition

- |  |  |
|--|--|
| (1) Class of shares to be acquired:        | Common stock of the Company  |
| (2) Total number of shares to be acquired: | Up to 4.8 million shares<br>(The percentage compared to the total number of shares outstanding: 1.04%) |
| (3) Aggregate amount of acquisition cost:  | Up to 20 billion yen   |
| (4) Period of acquisition:                 | From November 5, 2012 to December 10, 2012   |

(Reference)

The status of treasury stock as of September 30, 2012:

Total number of shares outstanding:	461,934,619 shares
Number of treasury stock:	6,030,016 shares

#####

For inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201, FAX:+81-3-5201-7473

<http://www.astellas.com/en>